Table 1.

Distribution of Eligibility for SGLT‐2 Inhibitors, GLP‐1RAs, or Both in Patients With Diabetes Mellitus Across Demographics and Comorbidities

	Total	SGLT‐2 Inhibitor		GLP‐1RA		SGLT‐2 Inhibitor and GLP‐1RA
	No.	No.	Weighted % [95% CI]	No.	Weighted % [95% CI]	No.	Weighted % [95% CI]
Overall	1104	548	52.6 [47.7–57.5]	344	32.8 [28.8–37.2]	267	26.6 [22.2–31.7]
Age, y
<65	577	234	44.0 [35.3–53.1]	149	27.2 [21.8–33.2]	103	20.9 [15.7–27.3]
≥65	527	314	64.4 [56.9–71.2]	195	40.6 [34.2–47.2]	164	34.4 [27.6–41.9]
Sex
Women	537	228	47.8 [39.8–55.9]	135	27.0 [21.6–33.3]	97	20.0 [14.0–27.7]
Men	567	320	57.2 [51.8–62.5]	209	38.3 [32.4–44.7]	170	32.9 [26.9–39.5]
Race/ethnicity
Non‐Hispanic White	345	208	57.4 [50.4–64.2]	148	38.2 [31.2–45.8]	124	32.6 [25.0–41.3]
Non‐Hispanic Black	271	122	42.3 [35.4–49.5]	71	24.7 [18.7–31.9]	58	18.9 [14.7–24.0]
Others	488	218	47.4 [41.4–53.5]	125	25.4 [20.3–31.2]	85	17.7 [13.4–23.1]
Health insurance	985	493	52.3 [46.7–57.9]	319	33.4 [28.7–38.5]	248	26.7 [21.5–32.7]
Comorbidities
Smoking	144	81	53.0 [39.4–66.1]	49	34.4 [24.2–46.3]	45	31.6 [22.0–43.2]
Central obesity	787	382	50.7 [44.8–56.7]	220	30.0 [25.8–34.6]	175	24.1 [18.7–30.5]
Hypertension	817	452	61.5 [56.0–66.8]	241	32.3 [26.8–38.4]	223	31.2 [25.7–37.2]
Dyslipidemia	863	446	55.1 [49.3–60.7]	230	28.5 [22.7–35.2]	212	27.2 [21.7–33.6]

GLP‐1RA indicates glucagon like peptide‐1 receptor agonist; and SGLT‐2, sodium glucose transporter‐2.